AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$VMD

Heltz Sabrina sold (to issuer) $34K of VMD

Heltz Sabrina sold (to issuer) 3,757 shares of VIEMED HEALTHCARE, INC. (VMD) at $8.94 on 2026-08-19.

Original reporting
SEC EDGAR · Heltz Sabrina
Published Aug 19, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 10:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VMD
Neutral
high confidence
Mentioned
$VMD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VMDNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market effect.

02

Market read

Minor insider sale; unlikely to move the stock significantly.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 3/10Novelty 4/10Timing: today

Background

Form 4 filing reports insider transactions; required by SEC for directors.

Company-level read

Ticker impact

$VMDNeutralHigh confidence
Context

Director Heltz Sabrina sold 3,757 shares for $33,587.58, reducing her holdings to 82,520 shares.

Expected impact

Minimal downward pressure, likely negligible.

Evidence & confidence

Sale size is small relative to float and market cap; typical for directors.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider sale could be interpreted as lack of confidence, but size is trivial.

Key entities

  • Company
    Viemed Healthcare, Inc.

    Issuer of the shares sold.

  • Director
    Heltz Sabrina

    Insider reporting the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VMD insider trading history →

Related articles

AUG 29
$VMDMedAI 8/10

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions

yahoo.com2 min
AUG 20
Med

Viemed Healthcare Announces New Share Repurchase Program of Up to 5% of Shares Outstanding – Minichart

Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.

minichart.com.sg2 min
AUG 11
$VMDMedAI 8/10

Viemed (VMD) Q2 2026 Earnings Call Transcript

Viemed Healthcare (VMD) reported Q2 2026 revenue of $78.1M, up 24% year over year, with ventilator patient counts reaching 12,635. Adjusted EBITDA was $13.7M (17.6% margin) and net income was $2.8M. Full-year 2026 revenue guidance was raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

fool.com6 min
AUG 6
$VMDMedAI 8/10

Viemed Healthcare Q2 Earnings Call Highlights

Viemed Healthcare (NASDAQ:VMD) reported Q2 updates on home respiratory and sleep therapies. Management cited improved ventilator patient growth and said PAP setups rose, with sleep patients up about 5% sequentially and 44% YoY. Equipment sales nearly doubled to $19M. Gross profit was $45M (57.7% margin). Full-year net revenue guidance raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

yahoo.com6 min